Chinese state-owned firm signs deal with Pfizer to supply Covid-19 pill


68c40803-064b-47ef-9e73-9d07e6f183d9_98dc2753

Pfizer’s Covid-19 pill is one step closer to clinical use in China, with state-owned China Meheco Corp securing a deal with Pfizer to commercialise the drug within the year.

The Chinese company had signed a contract with Pfizer and was authorised to supply Paxlovid in China during the 2022 agreement period, China Meheco said in a statement on Wednesday night.

Subscribe now and receive FREE sooka plan for 1 month.
T&C applies.

Monthly Plan

RM13.90/month

Annual Plan

RM12.33/month

Billed as RM148.00/year

1 month

Free Trial

For new subscribers only


Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!

SCMO , China , Covid-19 , Pills , Pfizer

   

Next In Aseanplus News

Asean news headlines as at 10pm on Tuesday (Nov 5)
Mount Fuji is still without its iconic snowcap for the first time in 130 years
Bernama, China Media Group exchange MOU to strengthen media cooperation
Thailand plans to resume talks with Cambodia over border disputes
Lao People’s Revolutionary Party calls for action to address economic woes
Myanmar ethnic groups slam China as they begin talks with India
Anwar, Li witness exchange of documents on BRI cooperation plan
Flight aborted after passenger claims engine caught fire in Papua
HK actor Gilbert Lam shares month-long health struggle, relies on walker to get around
How the US elections will impact the Philippines

Others Also Read